MD Anderson's David M. Gershenson, M.D., receives award for excellence

November 10, 2014

Houston, Texas -- For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society's (IGCS) Award of Excellence.

Gershenson, professor and past chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, received the award at the IGCS's 15th Biennial Meeting in Melbourne, Australia. William J. Hoskins, MD., of Memorial Sloan Kettering, also was honored with the distinction.

The IGCS is a not-for-profit, independent organization contributing to the prevention, treatment and study of gynecologic cancer, as well as improvement in the quality of life among women suffering from such diseases throughout the world.

In recognizing Dr. Gershenson, the organization notes him as an exemplar in forwarding the scientific knowledge of gynecological cancers, and, more specifically, of the non-epithelial ovarian cancers.

"Dr. Gershenson's role in the diagnosis and clinical management of these tumors has been of the top level globally. Many around the world, who are also accomplished and knowledgeable in this area, consult him about issues related to the care of women with these tumors," says the IGCS in a press release. "Through his generosity, countless patients beyond MD Anderson have benefited from his wisdom and unique breadth of experience."

Gershenson joined the MD Anderson faculty in 1979 and served as the departments chair 1998-2012. He focuses both his clinical and translational research on rare ovarian tumors, and in collaboration with several colleagues at MD Anderson and beyond, conducts clinical and translational studies of: low-grade serous tumors, clear cell carcinomas, mucinous carcinomas, malignant ovarian germ cell tumors, and sex cord-stromal ovarian tumors. Among Gershenson's myriad clinical research achievements are advancing the field in the understanding that low-grade serous carcinomas are relatively chemo-resistant. In addition, he's played a major role in developing clinical trials focusing on novel therapeutics for patients with rare ovarian cancers. His research also has reported the poor prognosis associated with advanced stage or recurrent ovarian clear cell and mucinous carcinomas. Since 1999, Gershenson has served as Co-Principal Investigator of MD Anderson's NCI-funded SPORE in Ovarian Cancer and, more recently, as a co-project leader, "Personalized Therapy for Women with Low-Grade Serous Carcinoma of the Ovary."

Gershenson notes that the principles that guide the field's care in treating women with rare ovarian cancers is much more evidenced-based than when he first started in the field 35 years ago.

"Also, the revolution of our understanding of the molecular biology and genetics of the disease has really transformed the field and has led to dramatic opportunities in personalized medicine, both in terms of discovery and for the benefit of patients. With this understanding, over the last decade, we have transitioned from treating all ovarian cancers identically, to targeting specific cancer subtypes, and being able to offer personalized care for women with these rarest of disease."

Gershenson's expertise in the field expands far beyond MD Anderson, with leadership roles in numerous national and international organizations, including: the NCI-sponsored cooperative group--NRG Oncology, chair of the Rare Tumor Committee, and principal investigator of an international trial between the NRG and a research group in UK for women with recurrent low-grade serous carcinoma of the ovary; co-chair of the NCI's Gynecologic Cancer Steering Committee, which approves all new phase III and randomized phase II clinical trials for gynecologic cancers in North America; chairman, Foundation for Women's Cancer, a national foundation of the Society of Gynecologic Oncologists, whose major missions include research grant funding and public education and awareness of gynecologic cancers; editor emeritus of the journal, Gynecologic Oncology, and a director of the American Board of Obstetrics and Gynecology, 2006-2014.

Of all his accomplishments, Gershenson says he's most proud of ushering in the next generation of gynecologic oncologists to make a difference in the lives of patients.

"I am truly honored by this award, but it's really a tribute to all the support I have received during my career during from family, friends and both senior and junior colleagues," said Gershenson. "Being the chair of the Department allowed me to recruit and mentor a wonderful group of individuals committed to making a difference for women in greatest need. Our patients teach us humility, priorities and the importance of living life to the fullest. In return, it's vital that we offer them the very best possible care."
-end-


University of Texas M. D. Anderson Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.